pioglitazone has been researched along with Myocardial Ischemia in 14 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone use is associated with a lower risk of dementia in patients with DM, particularly in those with a history of stroke or ischemic heart disease, suggesting the possibility of applying a personalized approach when choosing pioglitazone to suppress dementia in patients with DM." | 8.31 | Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke. ( Choi, DW; Ha, J; Kim, E; Kim, KJ; Kim, KY; Nam, CM, 2023) |
| "The present investigation was designed to study the cardioprotective effects of nicorandil and pioglitazone preconditioning in myocardial ischemia/reperfusion-induced hemodynamic, biochemical and histological changes in rats." | 7.77 | Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats. ( Agha, AM; Ahmed, LA; Attia, AS; Salem, HA, 2011) |
| " The effect of pioglitazone on composite endpoints was evaluated, including all-cause death, myocardial infarction (MI), and stroke, as well as safety events of edema and serious heart failure, in subgroups using nitrates, RAS blockers, or insulin at baseline." | 5.14 | Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). ( Charbonnel, B; Erdmann, E; Spanheimer, R, 2010) |
| "Pioglitazone use is associated with a lower risk of dementia in patients with DM, particularly in those with a history of stroke or ischemic heart disease, suggesting the possibility of applying a personalized approach when choosing pioglitazone to suppress dementia in patients with DM." | 4.31 | Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke. ( Choi, DW; Ha, J; Kim, E; Kim, KJ; Kim, KY; Nam, CM, 2023) |
| "The present investigation was designed to study the cardioprotective effects of nicorandil and pioglitazone preconditioning in myocardial ischemia/reperfusion-induced hemodynamic, biochemical and histological changes in rats." | 3.77 | Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats. ( Agha, AM; Ahmed, LA; Attia, AS; Salem, HA, 2011) |
| "Pioglitazone treatment might suppress in-stent neointimal proliferation and reduce incidence of TLR after PCI in patients with T2DM." | 2.74 | A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). ( Fitzgerald, PJ; Honda, Y; Ikeno, F; Ito, A; Kataoka, T; Kobayashi, Y; Okura, H; Sakanoue, Y; Shimeno, K; Taguchi, H; Takagi, T; Tamita, K; Toda, I; Waseda, K; Yamamuro, A; Yamasaki, M; Yanagi, S; Yoshikawa, J; Yoshiyama, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Ha, J | 1 |
| Choi, DW | 1 |
| Kim, KJ | 1 |
| Kim, KY | 1 |
| Nam, CM | 1 |
| Kim, E | 1 |
| Butterick, TA | 1 |
| Hocum Stone, L | 1 |
| Duffy, C | 1 |
| Holley, C | 1 |
| Cabrera, JA | 1 |
| Crampton, M | 1 |
| Ward, HB | 1 |
| Kelly, RF | 1 |
| McFalls, EO | 1 |
| Margolis, DJ | 1 |
| Hoffstad, O | 1 |
| Strom, BL | 1 |
| Singh, S | 1 |
| Furberg, CD | 1 |
| Ye, Y | 1 |
| Lin, Y | 1 |
| Perez-Polo, JR | 1 |
| Birnbaum, Y | 1 |
| Viljoen, A | 1 |
| Sinclair, A | 1 |
| Takagi, T | 1 |
| Okura, H | 1 |
| Kobayashi, Y | 1 |
| Kataoka, T | 1 |
| Taguchi, H | 1 |
| Toda, I | 1 |
| Tamita, K | 1 |
| Yamamuro, A | 1 |
| Sakanoue, Y | 1 |
| Ito, A | 1 |
| Yanagi, S | 1 |
| Shimeno, K | 1 |
| Waseda, K | 1 |
| Yamasaki, M | 1 |
| Fitzgerald, PJ | 1 |
| Ikeno, F | 1 |
| Honda, Y | 1 |
| Yoshiyama, M | 1 |
| Yoshikawa, J | 1 |
| Nissen, SE | 2 |
| Kaul, S | 1 |
| Bolger, AF | 1 |
| Herrington, D | 1 |
| Giugliano, RP | 1 |
| Eckel, RH | 1 |
| Rosen, CJ | 1 |
| Erdmann, E | 1 |
| Spanheimer, R | 1 |
| Charbonnel, B | 1 |
| Ahmed, LA | 1 |
| Salem, HA | 1 |
| Attia, AS | 1 |
| Agha, AM | 1 |
| Tomono, S | 1 |
| Uchiyama, T | 1 |
| Ohyama, Y | 1 |
| Lincoff, AM | 1 |
| Wolski, K | 1 |
| Nicholls, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Pioglitazone in Alzheimer Disease Progression[NCT00982202] | Phase 2 | 25 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for pioglitazone and Myocardial Ischemia
| Article | Year |
|---|---|
Safety and efficacy of rosiglitazone in the elderly diabetic patient.
Topics: Age Factors; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Fra | 2009 |
[Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
Topics: Acarbose; Cyclohexanes; Fasting; Glucose Intolerance; Glycation End Products, Advanced; Humans; Hype | 2005 |
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Ischemia | 2007 |
2 trials available for pioglitazone and Myocardial Ischemia
| Article | Year |
|---|---|
A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Glucose; California; Cell Proliferation; Coronary Angiog | 2009 |
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
Topics: Age of Onset; Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic An | 2010 |
9 other studies available for pioglitazone and Myocardial Ischemia
| Article | Year |
|---|---|
Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Ischemic Stroke; Myocardial Ischemia; Piogli | 2023 |
Pioglitazone increases PGC1-α signaling within chronically ischemic myocardium.
Topics: Animals; Chromatography, Liquid; Disease Models, Animal; Female; Heart; Hypoglycemic Agents; Myocard | 2016 |
Association between serious ischemic cardiac outcomes and medications used to treat diabetes.
Topics: Adult; Aged; Biguanides; Cohort Studies; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Ins | 2008 |
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Ischemia; Piogli | 2009 |
Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone.
Topics: Administration, Oral; Animals; Body Weight; Coronary Vessels; Data Interpretation, Statistical; Deca | 2008 |
Pioglitazone to reduce restenosis after bare-metal stent placement?
Topics: Angioplasty, Balloon, Coronary; Cell Proliferation; Coronary Restenosis; Diabetes Mellitus, Type 2; | 2009 |
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
Topics: American Heart Association; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heart Fa | 2010 |
Revisiting the rosiglitazone story--lessons learned.
Topics: Advisory Committees; Diabetes Mellitus, Type 2; Drug Labeling; Government Regulation; Humans; Hypogl | 2010 |
Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats.
Topics: Animals; Arrhythmias, Cardiac; Heart Rate; Ischemic Preconditioning, Myocardial; Male; Myocardial Is | 2011 |